Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors

Journal of Human Hypertension

Volumn 20, Issue 11, 2006, Pages 860-866

  Aksnes, T A ^a   Reims, H M ^a   Guptha, S ^b   Moan, A ^c   Os, I ^a   Kjeldsen, S E ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MSD (Norge) A/S   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLUCOSE; INSULIN; LOSARTAN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; INSULIN SENSITIVITY; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; VASODILATATION;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEART RATE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LIPIDS; LOSARTAN; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; URIC ACID; VASODILATION;

EID: 33750314218     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002087     Document Type: Article

References (26)

1. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991; 121(Part 2): 1268-1273.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365(9455): 217-223.
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782-787.
4. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type II diabetes: A systematic review. Diabetes Care 2004; 27(1): 247-255.
5. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type II diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med 2000; 342(13): 905-912.
6. Aksnes TA, Reims HM, Kjeldsen SE, Mancia G. Antihypertensive treatment and new-onset diabetes mellitus. Curr Hypertens Rep 2005; 7(4): 298-303.
7. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031.
8. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237(3): E214-E223.
9. Moan A, Nordby G, Os I, Birkeland KI, Kjeldsen SE. Relationship between hemorrheologic factors and insulin sensitivity in healthy young men. Metabolism 1994; 43(4): 423-427.
10. Fossum E, Höieggen A, Moan A, Nordby G, Kjeldsen SE. Insulin sensitivity relates to other cardiovascular risk factors in young men: validation of some modifications of the hyperinsulinaemic, isoglycaemic glucose clamp technique. Blood Press Suppl 1997; 2: 113-119.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-419.
12. Moan A, Höieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14(9): 1093-1097.
13. Howard BV, Rodriguez BL, Bennett PH, Harris MI, Hamman R, Kuller LH et al. Prevention conference VI: Diabetes and cardiovascular disease: writing group I: Epidemiology. CircElation 2002; 105(18): e132-e137.
14. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003; 17(3): 305-322.
15. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6(1): 45-86.
16. Lender D, rauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999; 12(3): 298-303.
17. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22(8): 1453-1458.
18. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101(14): 1653-1659.
19. Julius S, Gudbrandsson T, Jamerson K, Tariq SS, Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9(11): 983-986.
20. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43(5): 993-1002.
21. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109(17): 2054-2057.
22. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41(2): 127-133.
23. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type II diabetes by formation of fat cells. Hypertension 2002; 40(5): 609-611.
24. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3(3): 185-188.
25. Olsen MH, Fossum E, Höieggen A, Wachtell K, Hjerkinn E, Nesbitt SD et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23(4): 891-898.
26. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B et al. Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002; 20(9): 1879-1886.